医学
他汀类
横纹肌溶解症
血脂异常
肌痛
中止
肌病
内科学
吉非罗齐
类降脂药
糖尿病
Evolocumab公司
不利影响
以兹提米比
痛风
内分泌学
胆固醇
载脂蛋白B
载脂蛋白A1
标识
DOI:10.1016/j.ecl.2022.01.004
摘要
This article reviews the safety of statins and non-statin medications for management of dyslipidemia . Statins have uncommon serious adverse effects: myopathy/ rhabdomyolysis , which resolve with statin discontinuation, and diabetes, usually in people with risk factors for diabetes. The CVD benefit of statins far exceeds the risk of diabetes. Statin myalgia , without CK elevation, is likely caused by muscle symptoms with another etiology, or the nocebo effect . Notable adverse effects of non-statin medicines include injection site reactions (alirocumab, evolocumab , inclisiran), increased uric acid and gout (bempedoic acid), atrial fibrillation/flutter (omega-3-fatty acids), and myopathy in combination with a statin (gemfibrozil).
科研通智能强力驱动
Strongly Powered by AbleSci AI